Table 2 Change in EQ-5D dimensions from injection cycle baseline to 4 weeks post-injection (FAS)
From: Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
Dimension | Injection cycle | N | Nobs | Improvement, n (%) | No change, n (%) | Worsening, n (%) |
|---|---|---|---|---|---|---|
Mobility | 1 | 155 | 155 | 18 (11.6) | 135 (87.1) | 2 (1.3) |
2 | 152 | 149 | 11 (7.2) | 136 (89.5) | 2 (1.3) | |
3 | 140 | 138 | 6 (4.3) | 128 (91.4) | 4 (2.9) | |
Self-care | 1 | 155 | 155 | 19 (12.3) | 123 (79.4) | 13 (8.4) |
2 | 152 | 148 | 7 (4.6) | 127 (83.6) | 14 (9.2) | |
3 | 140 | 138 | 11 (7.9) | 121 (86.4) | 6 (4.3) | |
Usual activities | 1 | 155 | 155 | 20 (12.9) | 126 (81.3) | 9 (5.8) |
2 | 152 | 148 | 18 (11.8) | 116 (76.3) | 14 (9.2) | |
3 | 140 | 138 | 8 (5.7) | 126 (90.0) | 4 (2.9) | |
Pain/discomfort | 1 | 155 | 155 | 40 (25.8) | 105 (67.7) | 10 (6.5) |
2 | 152 | 149 | 32 (21.1) | 105 (69.1) | 12 (7.9) | |
3 | 140 | 138 | 29 (20.7) | 102 (72.9) | 7 (5.0) | |
Anxiety/depression | 1 | 155 | 155 | 27 (17.4) | 119 (76.8) | 9 (5.8) |
2 | 152 | 149 | 18 (11.8) | 121 (79.6) | 10 (6.6) | |
3 | 140 | 138 | 18 (12.9) | 111 (79.3) | 9 (6.4) |